Paul Stuka Buys 65,626 Shares of InspireMD (NYSE:NSPR) Stock

InspireMD, Inc. (NYSE:NSPR) Director Paul Stuka bought 65,626 shares of the company’s stock in a transaction that occurred on Friday, May 8th. The shares were bought at an average price of $1.16 per share, for a total transaction of $76,126.16. Following the transaction, the director directly owned 622,871 shares in the company, valued at $722,530.36. This trade represents a 11.78% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Paul Stuka also recently made the following trade(s):

• On Monday, May 11th, Paul Stuka purchased 10,000 shares of InspireMD stock. The stock was bought at an average price of $1.19 per share, with a total value of $11,900.00.
• On Thursday, May 7th, Paul Stuka purchased 6,378 shares of InspireMD stock. The stock was bought at an average cost of $1.15 per share, with a total value of $7,334.70.
• On Wednesday, May 6th, Paul Stuka acquired 1,517 shares of InspireMD stock. The shares were bought at an average price of $1.12 per share, for a total transaction of $1,699.04.

InspireMD Price Performance

NSPR stock opened at $1.17 on Thursday. The stock has a market capitalization of $54.80 million, a PE ratio of -1.56 and a beta of 0.82. The company’s 50-day moving average is $1.46 and its 200-day moving average is $1.72. InspireMD, Inc. has a 1 year low of $1.02 and a 1 year high of $2.93.

Hedge Funds Weigh In On InspireMD

A number of hedge funds have recently added to or reduced their stakes in the stock. Aberdeen Group plc purchased a new stake in shares of InspireMD in the third quarter worth approximately $5,979,000. Rosalind Advisors Inc. boosted its position in shares of InspireMD by 70.6% during the third quarter. Rosalind Advisors Inc. now owns 3,905,743 shares of the company’s stock valued at $9,413,000 after buying an additional 1,616,644 shares during the last quarter. Velan Capital Investment Management LP grew its holdings in InspireMD by 137.1% during the third quarter. Velan Capital Investment Management LP now owns 2,143,698 shares of the company’s stock worth $5,166,000 after buying an additional 1,239,669 shares in the last quarter. Parkman Healthcare Partners LLC raised its position in InspireMD by 97.6% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 2,440,633 shares of the company’s stock valued at $5,882,000 after buying an additional 1,205,328 shares during the last quarter. Finally, Nantahala Capital Management LLC raised its position in InspireMD by 45.7% in the 3rd quarter. Nantahala Capital Management LLC now owns 3,376,484 shares of the company’s stock valued at $8,137,000 after buying an additional 1,058,467 shares during the last quarter. Institutional investors and hedge funds own 44.78% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on NSPR. Maxim Group began coverage on InspireMD in a research note on Monday, February 2nd. They issued a “buy” rating and a $6.00 price objective for the company. Loop Capital set a $5.00 target price on InspireMD in a research report on Tuesday, February 24th. Piper Sandler reiterated an “overweight” rating and issued a $3.00 target price (down from $4.00) on shares of InspireMD in a report on Tuesday, May 5th. Finally, Lake Street Capital set a $4.00 price target on shares of InspireMD in a research report on Monday, May 4th. Three investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, InspireMD has a consensus rating of “Buy” and an average price target of $4.50.

InspireMD Company Profile

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.